Healthcare giant Johnson & Johnson (NYSE: JNJ – $103.38) announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion. Cordis is a leader in the development and manufacture of interventional vascular technology with 2014 net revenues of approximately $780 million. J&J is working to pare its wide-ranging portfolio to focus on higher-growth businesses and reduce costs. Johnson & Johnson, a pioneer in stents that prop open clogged heart arteries, said years ago that it would get out of the vascular implant business. The company, however, remains committed to the fight against cardiovascular disease through its fast-growing electrophysiology unit, Biosense Webster, in the Medical Devices segment and its leading cardiovascular medicine, XARELTO®, in the Pharmaceutical segment. The shares of JNJ have been in a trading range over the past ten months ($95 – $109), but longer-term total-return potential is decent, thanks in large part to the above-average dividend, yielding 2.7%, and should remain a core holding for the conservative income minded.